Discontinued — last reported Q4 '24
Edwards Lifesciences Decrease in Unrecognized Tax Benefits is Reasonably Possible increased by 4.0% to $391.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 17.8%, from $332.70M to $391.90M. Over 5 years (FY 2020 to FY 2025), Decrease in Unrecognized Tax Benefits is Reasonably Possible shows an upward trend with a 31.7% CAGR.
other_decrease_in_unrecognized_tax_benefits_is_reasonabl_fc57b8| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $115.30M | $128.50M | $135.10M | $147.70M | $158.30M | $169.20M | $182.10M | $194.30M | $205.10M | $226.40M | $250.70M | $265.90M | $275.40M | $326.10M | $319.90M | $332.70M | $346.60M | $362.60M | $377.00M | $391.90M |
| QoQ Change | — | +11.4% | +5.1% | +9.3% | +7.2% | +6.9% | +7.6% | +6.7% | +5.6% | +10.4% | +10.7% | +6.1% | +3.6% | +18.4% | -1.9% | +4.0% | +4.2% | +4.6% | +4.0% | +4.0% |
| YoY Change | — | — | — | — | +37.3% | +31.7% | +34.8% | +31.6% | +29.6% | +33.8% | +37.7% | +36.9% | +34.3% | +44.0% | +27.6% | +25.1% | +25.9% | +11.2% | +17.8% | +17.8% |